Heart Failure

ACC 2023. In an analysis of patients with heart failure, never having been married was associated with worse survival compared with having been married.

Your daily dose of clinical news you may have missed.

After hospital discharge for heart failure, adults treated with either furosemide or torsemide had similar mortality rates, according to results from the TRANSFORM-HF clinical trial.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Approved in 2020 as Nexletol, bempedoic acid as the first ATP citrate lyase inhibitor and oral non-statin therapy to meet the MACE-4 primary endpoint.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.

A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.

Patients with HFpEF who significantly restrict salt consumption have increased risk for cardiovascular and HF events and HF hospitalization, according to new research.

Chronic kidney disease is underdiagnosed and undertreated across major Western countries, according to findings of the new CaReMe CKD study.

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.

ACC.22: Findings from 3 studies show drinking 2-3 cups of coffee per day is associated with a reduced risk of CVD, abnormal heart rhythms, and mortality.

The landmark approval for the SGLT-2 inhibitor will open access to treatment for the ~ 3 million adults with heart failure with preserved ejection fraction.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.

Treatment with aspirin of patients with cardiovascular risk factors was consistently associated with a greater than 25% risk of incident HF, another strike against the OTC antithrombotic.

Smoking was associated with earlier onset of cardiovascular disease, by 5.1 years for men and 3.8 years for women, the new study found.